C ardiovascular magnetic resonance (CMR) is an accepted noninvasive investigation for the detection of coronary heart disease (CHD). It is attractive because of its lack of ionizing radiation, high spatial resolution, and versatility in providing morphologic and functional cardiac assessment in a single study (1) (2) (3) .
The CE-MARC (Clinical Evaluation of MAgnetic Resonance imaging in Coronary heart disease) study (4) was the largest prospective evaluation to date of CMR versus nuclear myocardial perfusion imaging using single-photon emission computed tomography (SPECT). It was designed to establish the diagnostic performance of multiparametric CMR in unselected patients with suspected CHD and to compare the diagnostic performance of CMR and SPECT for the detection of significant CHD, using X-ray angiography as the reference standard (5) . In line with previous smaller studies (6 ,7) , CE-MARC demonstrated a high diagnostic accuracy of CMR, with higher sensitivity and negative predictive value compared with SPECT (4). scheduled to have CMR and SPECT (in random order), followed by X-ray coronary angiography (the reference standard) within 4 weeks regardless of the treating physician's chosen clinical pathway (4, 5) . After X-ray angiography, the SPECT result could be made available on request to enable a decision about revascularization (masking the treating clinician to this result was deemed unethical); however, CMR results were kept masked.
The study was conducted in accordance with the Declaration of Helsinki (2000) and approved by the United Kingdom National Research Ethics Service (approval 05/Q1205/126); all patients provided informed written consent. Extended 5-year follow-up was conducted with approval from the National Research Ethics Service (approval 14/YH/0137) and approval under Section 251 of the National Health Service Act 2006 (approval 14/CAG/1018).
Image Acquisition and Analysis
In CE-MARC, CMR and SPECT scans were analyzed in a blinded manner by paired readers with more than 10 years' experience in their respective modalities. The multiparametric CMR (1.5-T Philips Intera [Philips]) protocol comprised stress perfusion (adenosine, 140 μg/kg per minute for ≥4 minutes), cine imaging, rest perfusion, coronary MR angiography, and late gadolinium enhancement (LGE). The CMR result was positive if any of the following was found: evidence of regional wall-motion abnormality, regional hypoperfusion (ischemia) on stress compared with rest CMR perfusion scans, coronary artery stenosis on MR angiography (≥50% left main stem; ≥70% in any other vessel ≥2.5 mm in diameter), or myocardial infarction on LGE images (4, 5) . If all components were negative, the CMR study was judged to be negative.
For SPECT, a dedicated cardiac gamma camera was used for image acquisition (Cardio-C [Mediso]). Patients underwent a 2-day protocol using 99m Tctetrofosmin with a standard dose of 400 MBq, adjusted by weight to a maximum of 600 MBq per examination. Stress and rest electrocardiography gated images were acquired by using an identical intravenous adenosine protocol to that in CMR. Diagnosis was based on all available SPECT data and an overall clinical judgment. Rest and stress perfusion and regional wall motion were reviewed, and ancillary findings (right ventricular uptake and transient ischemic dilatation) were recorded. The study was considered abnormal if any of the components was abnormal (6 -8) . Specific imaging and reporting parameters for CMR and SPECT are described elsewhere (4, 9) .
Follow-up and Clinical End Points
Annual follow-up for 5 years was planned for all recruited patients. A detailed medical history since randomization was obtained from all hospital and general practitioners' records and cross referenced to information obtained by direct telephone contact with each patient. Mortality and cause of death were obtained from the Office for National Statistics via the Health and Social Care Information Centre.
A MACE was defined as the composite end point of cardiovascular death, myocardial infarction/acute coronary syndrome, unscheduled coronary revascularization or hospital admission for any cardiovascular cause (stroke/transient ischemic attack, heart failure, arrhythmia) (7) . "Hard" clinical events were defined as a composite of cardiovascular death and nonfatal myocardial infarction/acute coronary syndrome, to allow direct comparison with prior published outcome data for CMR and SPECT. Unscheduled coronary revascularization was defined as any revascularization that occurred owing to clinical deterioration and excluded procedures that were planned on the basis of the index coronary angiography results. All clinical events were adjudicated by a clinical events committee that was blinded to any of the CMR or SPECT results.
Statistical Analysis
Statistical analyses were performed independently by the Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom. The study was prospectively powered to demonstrate the prognostic value of CMR and SPECT with follow-up for at least 3 years, on the basis of a predicted clinical event rate of approximately 3% per year (5) . Owing to the lower overall event rate per year seen within the study, follow-up was extended by the Trial Steering Committee to 5 years. Both the total number of events and the first adjudicated event per patient were summarized; the main analysis was based on the first adjudicated event. Only patients with CMR, SPECT, and angiography results, with follow-up data, were included in this analysis.
Prediction of first MACE was assessed by using univariable (log-rank test) and multivariable analysis (Cox proportional hazards regression modeling). The major cardiovascular risk factors of age, sex, total cholesterol level, hypertension, smoking, diabetes, and family history were included in the multivariable model because they are known to have a strong association with MACEs. Additional analysis was done with adjustment for the risk score of Genders and colleagues (10) instead of the individual cardiovascular risk factors. Further analyses were done by using the above methods to adjust for the effect of X-ray angiography results. Stratified Cox proportional hazards modeling was done to account for initial patient treatment. Difference in the Akaike Information Criterion was used to determine which model better explained the variation in time to MACE between the multivariable models, with a value greater than 10 taken to indicate a better model (11) . Kaplan-Meier curves were produced for time to MACE. Patients who did not experience a MACE were recorded as the last time they were known to be alive and MACE-free.
Statistical analyses were performed with SAS software, version 9.4 (SAS Institute), with hypothesis testing using a 2-sided significance level of 5% (5).
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RESULTS

Baseline Characteristics
Between March 2006 and August 2009, 752 patients with suspected angina underwent prospective randomization. Follow-up was obtained in 99% of patients; 5 patients (1%) were lost to follow-up (all had emigrated), and 3 (0.4%) withdrew their consent. Median follow-up was 80.7 months (interquartile range, 68.3 to 91.6 months). The main outcome population comprised 628 patients who had CMR, SPECT, and angiography results ( Figure 1) . Baseline characteristics of all study patients and the final analysis population are shown in Table 1 .
Events at 5 Years
In the full study population of 752 patients, 204 MACEs occurred. In the analysis population of 628 patients, 171 MACEs occurred in 104 patients (16.6%). Table 2 provides a detailed breakdown of all MACEs and the first adjudicated event for each patient for both the full study population and the analysis population. In addition, 43 and 32 noncardiac deaths occurred in the full study population and the analysis population, respectively; these are not included in the MACE end point.
There were 33 (4.4%) hard clinical events in the full study population and 25 (4.0%) in the analysis population. Abnormal CMR and SPECT findings were associated with similar rates of MACEs (25.2% and 21.2%, respectively) and hard clinical events (7.9% and 7.4%). Normal CMR and SPECT findings were associated with very low and similar event rates for MACE (10% and 14.1%) and hard clinical events (1.4% and 2.5%). In comparison, significant stenosis or normal findings on angiography were associated with MACE rates of 25.4% and 11.1%, respectively. Event rates were similar between patients who were revascularized and those who were not (19% vs. 15.6%), with higher event rates for patients who had abnormal rather than normal findings on CMR or angiography, regardless of whether they were revascularized. In contrast, for SPECT, event rates were higher for patients with a normal result who were revascularized than for those who were not revascularized ( Table 3) . Figure 2 shows the difference in the Kaplan-Meier curves by baseline CMR, SPECT, and angiography result.
Prediction of MACE
In multivariable analysis, only CMR remained significantly associated with time to MACE after adjustment for the predefined major cardiovascular risk factors (HR, 2.34 [CI, 1.51 to 3.63]; P = 0.001); the CMR model explained variation in the time to MACE better than the SPECT model did (difference in Akaike Information Criterion, 13.52 vs. 0.68) ( Table 4 ). In addition, CMR remained a significant predictor of MACE after the angiography result was added to the multivariable models (HR, 1.81 [CI, 1.05 to 3.14]; P = 0.033) (Appendix Table 1 , available at www.annals.org) and when the multivariable analysis was stratified by initial treatment (HR, 2.8 [CI, 1.74 to 4.5]; P < 0.001) (Appendix Table 2 , available at www.annals.org), whereas SPECT did not. In all cases, CMR better explained the variation in the models. Adjustment for the Genders risk score made little difference to the models (Appendix Table 3 , available at www.annals.org).
When we compared the further value of adding CMR to a model containing SPECT and the predefined cardiovascular risk factors, and the further value of adding SPECT to a model containing CMR, only CMR provided additional value (likelihood ratio chi-square value, 12.232 for CMR [P < 0.001] and 0.007 for SPECT [P > 0.20]). The multivariable model with CMR explained more of the variation than SPECT (difference in Akaike Information Criterion, 10.85 vs. 1.99).
DISCUSSION
The primary analysis of CE-MARC has shown that in a large unselected patient population with suspected angina, both CMR and SPECT have a high diagnostic accuracy for detection of significant CHD (5). The current preplanned long-term outcome analysis from CE-MARC represents the first comparison of prospective prognostic data for CMR and SPECT in the same patient population, and has shown that 1) at a minimum of 5 years of follow-up, both abnormal CMR and SPECT are strong independent predictors of a MACE, with CMR better than SPECT at explaining the variation in time to a MACE, and 2) only CMR significantly adds to prediction of time to a MACE over and above major cardiovascular risk factors, angiographic findings, or the effect of initial treatment, with CMR better than SPECT at explaining the variation in time to a MACE. These findings demonstrate that CMR is a robust alternative to SPECT in predicting patient outcome and adds further weight to the growing evidence base for ACEI = angiotensin-converting enzyme inhibitor; ACS = acute coronary syndrome; AMI = acute myocardial infarction; ARB = angiotensin II receptor blocker; CMR = cardiovascular magnetic resonance; LAD = left anterior descending; LCx = left circumflex; LMS = left main stem; PCI = percutaneous coronary intervention; RCA = right coronary artery; SPECT = single-photon emission computed tomography. * Data are means (SDs), unless otherwise stated. † Based on a total sample of 692 patients and a sample with assessable imaging of 576 patients. The Framingham risk score is the risk for an event in the absence of chest pain over 10 y. Patients with previous coronary heart disease had no risk score calculated; those older than 75 y were assumed to be 75 y of age (12) . ‡ Based on a total sample of 726 patients and a sample with assessable imaging of 628 patients. Includes patients with completed or partly completed noninvasive test results.
ORIGINAL RESEARCH Prognostic Value of CMR and SPECT in Suspected Coronary Heart Disease
CMR in the diagnosis and management of patients with suspected CHD. The prognostic SPECT results from CE-MARC are in line with those of numerous previous studies of SPECT (13) (14) (15) (16) (17) (18) (19) (20) (21) . Myocardial perfusion imaging with SPECT has independent and incremental prognostic value after both clinical and physiologic stress (exercise) variables are considered. In particular, a normal SPECT scan is associated with very low risk for future cardiac events (13) (14) (15) (16) (17) 22) , whereas an abnormal scan is associated with intermediate to high risk for future cardiac events, depending on the degree of the abnormality (14, 15, 18 -21) . Furthermore, SPECT can be used to guide clinical management by identifying patients with the greatest potential survival benefit from coronary revascularization (23).
Although the evidence base is much smaller, CMR has also been shown to have prognostic value in patients with stable CHD. For example, myocardial ischemia detected by CMR stress perfusion or dobutamine stress CMR can identify patients at high risk for subsequent cardiac death and nonfatal myocardial infarction (24 -26) . In addition, myocardial scar detected by LGE CMR provides strong and complementary prognostic information, and the presence of LGE in patients without an inducible perfusion abnormality is associated with a greater than 11-fold increase in the HR for hard cardiovascular events (26) . Recently, the first systematic review and meta-analysis of CMR prognosis studies has shown that CMR can provide excellent prognostic stratification of patients with known or suspected coronary artery disease, similar to published SPECT data (27) . Of note, however, the previously published large SPECT studies were retrospectively designed and were heterogeneous for population, perfusion tracer, and scanning protocol. Similarly, all previous CMR outcome studies have had a retrospective design and have evaluated ischemia and scar separately. CE-MARC is the first large-scale prospective study to provide prognostic data for both multiparametric CMR and SPECT in the same unselected patient population. All patients with suspected angina enrolled in CE-MARC were prospectively scheduled for CMR, SPECT, and X-ray angiography (regardless of the noninvasive imaging results) at the time of recruitment, to minimize selection bias. It is also important to note that almost 100% of patients were successfully followed up for at least 5 years. These design characteristics make CE-MARC a powerful resource to determine the relative prognostic value of CMR and SPECT in the setting of suspected stable CHD.
In CE-MARC, normal findings on either CMR or SPECT were associated with a very low annual rate of hard cardiovascular events, which is in line with previous SPECT studies (18, 28) and similar to that of the general population in industrialized countries. The difference in the prediction of risk seen in this study is likely a reflection of the higher diagnostic accuracy of CMR compared with SPECT in detecting both ischemia and scar. For ischemia detection, a recent meta- (32) . CE-MARC has thus shown that the higher diagnostic accuracy of a combined CMR assessment of ventricular function, perfusion, and scar compared with a similar SPECT assessment translates into a superior prognostic performance of CMR in patients with suspected CHD.
The limitations of CE-MARC have been reported elsewhere (4) and include the single-center design, although the study was conducted in an institution with a high volume of CMR and SPECT. Any extrapolation to low-volume centers should be done with caution. However, a single site and unified pharmacologic stress protocol ensured consistency in CMR and SPECT and improved direct comparison between the modalities.
We did not use CT correction for SPECT attenuation artifacts; this is an important issue in nuclear myocardial perfusion imaging, because these artifacts are known to lead to false-positive perfusion defects (8) . However, CT attenuation correction was not standard in most nuclear institutions worldwide at the time of recruitment, and its use remains controversial (33, 34) . We integrated the findings from gated SPECT to differentiate real perfusion defects from artifacts (35) , which has been shown to improve the prognostic value of SPECT (13) , as per the European and U.S. guidelines for nuclear cardiology (36, 37) . A larger study or longer follow-up may have demonstrated that SPECT was also an independent predictor in the multivariable model.
Finally, this was an observational study of both modalities in the same patient population, rather than a randomized trial of each modality showing their direct effect on outcomes. This means that direct statistical comparison of SPECT and CMR cannot be done. In addition, because results of CMR, SPECT, and angiography are highly correlated, cautious interpretation of the multivariable models that include angiography is required.
In conclusion, 5-year follow-up of CE-MARC demonstrates that compared with SPECT, CMR was a stronger predictor of risk for a MACE, independent of clinical cardiovascular risk factors, angiography result, or initial patient treatment. This further supports the role of CMR as an alternative to SPECT for the diagnosis and management of patients with suspected CHD.
